Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for psoriasis and atopic dermatitis. The company has decided to discontinue development of the drug. Separately, a surprise FDA inspection is underway at Sun Pharma’s Halol manufacturing facility.
AI may hurt IT today, but it could create the sector’s next growth engine: Baroda BNP Paribas MF
AI may disrupt traditional revenue streams in India’s $280-billion IT services industry, but Rohan Korde of Baroda BNP Paribas Mutual Fund believes it could also